Population pharmacokinetics of valproate in Mexican children with epilepsy

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 9, 2008, Pages 511-520

  Correa, Tania ^a   Rodríguez, Idelfonso ^b   Romano, Silvia ^a  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b HOSPITAL CENTRAL DR IGNACIO MORONES PRIETO   (Mexico)

Author keywords

Children; Epilepsy; NONMEM; Pharmacokinetics; Valproate

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL; VALPROATE MAGNESIUM;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; EPILEPSY; FEMALE; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; MEXICO; PLASMA PROTEIN BINDING; POPULATION MODEL;

ADOLESCENT; ANTICONVULSANTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; MEXICAN AMERICANS; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; VALPROIC ACID;

EID: 59849083881     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.636     Document Type: Article

References (37)

1. Perucca E. Pharmacological and therapeutic properties of valproate. Drugs 2002; 16: 695-714.
2. Rabasseda X. Magnesium valproate: A broad-spectrum anticonvulsant agent. Clinical Review. Drugs Today 1995; 31: 185-190.
3. Rabasseda X. Indicaciones para el uso de Valproato de magnesio. Drugs Today 2000; 36(Suppl 1): 1-2.
4. Sánchez-Alcaraz A, Quintana MB, Rodríguez I. Valproic acid clearance in children with epilepsy. J Clin Pharm Ther 1998; 23: 31-34.
5. Blanco-Serrano B, Otero MJ, Santos Buelga D, García-Sánchez MJ, Serrano J, Domínguez-Gil A. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos 1999; 20: 233-240.
6. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007; 46: 271-279.
7. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005; 15: 779-786.
8. Almeida AM, Falcão AC, Sales F et al. Kinetic profile of carbamazepine in an adult Portuguese outpatient population. J Clin Pharm Ther 1998; 23: 315-321.
9. Chan E, Ti TY, Lee HS. Population pharmacokinetics of phenytoin in Singapore Chinese. Eur J Clin Pharmacol 1990; 39: 177-181.
10. Goto S, Seo T, Murata T et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit 2007; 29: 118-121.
11. Valodia P, Seymour MA, Miller R, McFadyen ML, Folb PI. Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa. Ther Drug Monit 1999; 21: 57-62.
12. Yukawa E, Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach. J Clin Pharm Ther 2006; 31: 275-282. DOI: 10.1111/j.1365-2710.2006.00712.x.
13. Blanco-Serrano B, Otero MJ, Santos Buelga D, García-Sánchez MJ, Serrano J, Domínguez-Gil A. Valproate population pharmacokinetics in children. J Clin Pharm Ther 1999; 24: 73-80.
14. Park HM, Kang SS, Lee YB et al. Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther 2002; 27: 419-425.
15. Desoky E, Fuseau E, Din Amry S, Cosson V. Pharmacokinetic modeling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol 2004; 59: 783-790.
16. Jiang D, Wang L. Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. Acta Pharmacol Sin 2004; 25: 1576-1583.
17. Jiang D, Wang L, Wang Y, Li L, Lu W, Bai X. Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta Pharmacol Sin 2007; 28: 1677-1684. DOI: 10.1111/j.1745-7254.2007.00704.x.
18. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
19. Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
20. Cloyd JC, Fisher JH, Kriel RI, Kraus DM. Valproic acid pharmacokinetic in children. IV: Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 1993; 53: 22-29.
21. Botha JH, Gray AL, Miller R. A model for estimating individualized valproate clearance values in children. J Clin Pharmacol 1995; 35: 1020-1024.
22. MacKichan JJ. Valproic Acid. In A Textbook for the Clinical Application of Therapeutic Drug Monitoring, Taylor WJ, Diers Caviness MH (eds). Abbott Laboratories, Diagnostic Division: Irving Texas, 1986; 269-280.
23. Sheiner LB, Rosenberg B, Marathe VV. Estimations of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-479.
24. Sheiner LB, Beal S. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512.
25. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 1997; 37: 1160-1167.
26. Yukawa E, Nonaka T, Yukawa M, Higuchi S, Kuroda T, Goto Y. Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patient. J Clin Pharm Ther 2003; 28: 497-504.
27. Hall K, Otten N, Johnson B, Irvine-Meek J, Leroux M, Seshia S. A multivariate analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. J Clin Pharmacol 1985; 25: 261-268.
28. Abadin JA, Duran JA, Sánchez A, Serrano JB. Total and free valproic acid: plasma level/dose ratio in monotherapy. Methods Find Exp Clin Pharmacol 1991; 13: 221-225.
29. Martin ES, Crismon ML, Godley PJ. Postinduction carbamazepine clearance in adult psychiatric population. Pharmacotherapy 1991; 11: 296-302.
30. Suzuki Y, Cox S, Hayes J, Walson PD. Carbamazepine age-dose ratio relationship in children. Ther Drug Monit 1991; 13: 201-208.
31. Patsalos PN, Froscher W, Pisani F. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-385.
32. Chiba K, Suganuma T, Ishizake T, Iriki T, Hori M. Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug therapy. J Pediatr 1985; 106: 653-658.
33. Cloyd JC, Kriel RI, Fisher JH. Valproic acid pharmacokinetic in children. II: Discontinuation of concomitant antiepileptic drug therapy. Neurology 1985; 35: 1623-1627.
34. Riva R, Albani F, Conti M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs: clinical considerations. Clin Pharmacokinet 1996; 31: 470-493.
35. Summers B, Summers RS. Carbamazepine clearance in paediatric epilepsy patients: influence of body mass, dose, sex and co-medication. Clin Pharmacokinet 1989; 17: 208-216.
36. Yukawa E. A feasibility study of the multiple-peak approach for pharmacokinetic screening: population based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. J Pharm Pharmacol 1995; 8: 1048-1052.
37. FDA. Guidance for Industry - Population pharmacokinetics Website. http://www.fda.gov/cder/guidance/1852fnl.pdf [22 January 2006].